Molecular genetics of quantitative fibrinogen disorders

Rosanna Asselta, S. Spena, S. Duga, M. L. Tenchini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Fibrinogen is a complex glycoprotein involved in the final step of the coagulation cascade as the precursor of fibrin monomers that participate in the formation of the haemostatic plug. Three genes (FGA, FGB, and FGG) clustered on chromosome 4q31.3-4q32.1 encode the three polypeptide chains (Aα Bβ, and γ), which in a pairwise fashion form the hexameric circulating molecule. Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen. Patients affected by CAF (Mendelian Inheritance in Man, [MIM] #202400) or severe hypofibrinogenemia (MIM+134820, *134830, and *134850) may experience bleeding manifestations varying from mild to catastrophic. Although many cases of fibrinogen deficiencies have been described from a clinical point of view, only in a minority of cases the causal mutation was identified. The genetic defects so far described, most unique for any analyzed family, are invariantly located in the fibrinogen cluster; for only few of them the pathogenic role either at the protein or at the mRNA level has been investigated. This review, besides providing a concise description of the main structural and functional properties of fibrinogen and giving an overview of the clinical manifestations, the laboratory diagnosis and therapeutic approches, will be focused on the present knowledge on the genetic basis of quantitative fibrinogen deficiencies. Our systematic analysis of the available clinical and genetic data on these disorders evidences their high allelic heterogeneity, the existence of different pathogenic mechanisms, and the absence of strong genotype/phenotype correlations.

Original languageEnglish
Pages (from-to)163-173
Number of pages11
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume5
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Afibrinogenemia
Fibrinogen
Molecular Biology
Coagulants
Proteins
Clinical Laboratory Techniques
Genetic Association Studies
Hemostatics
Glycoproteins
Chromosomes
Hemorrhage
Antigens
Messenger RNA
Peptides
Mutation
Genes
Therapeutics

Keywords

  • Afibrinogenemia
  • Diagnosis
  • Fibrinogen
  • Hypofibrinogenemia
  • Molecular basis
  • Mutational spectrum
  • Symptoms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Molecular genetics of quantitative fibrinogen disorders. / Asselta, Rosanna; Spena, S.; Duga, S.; Tenchini, M. L.

In: Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 5, No. 2, 04.2007, p. 163-173.

Research output: Contribution to journalArticle

@article{9ae1554afe024ad0978f1989a424cb15,
title = "Molecular genetics of quantitative fibrinogen disorders",
abstract = "Fibrinogen is a complex glycoprotein involved in the final step of the coagulation cascade as the precursor of fibrin monomers that participate in the formation of the haemostatic plug. Three genes (FGA, FGB, and FGG) clustered on chromosome 4q31.3-4q32.1 encode the three polypeptide chains (Aα Bβ, and γ), which in a pairwise fashion form the hexameric circulating molecule. Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen. Patients affected by CAF (Mendelian Inheritance in Man, [MIM] #202400) or severe hypofibrinogenemia (MIM+134820, *134830, and *134850) may experience bleeding manifestations varying from mild to catastrophic. Although many cases of fibrinogen deficiencies have been described from a clinical point of view, only in a minority of cases the causal mutation was identified. The genetic defects so far described, most unique for any analyzed family, are invariantly located in the fibrinogen cluster; for only few of them the pathogenic role either at the protein or at the mRNA level has been investigated. This review, besides providing a concise description of the main structural and functional properties of fibrinogen and giving an overview of the clinical manifestations, the laboratory diagnosis and therapeutic approches, will be focused on the present knowledge on the genetic basis of quantitative fibrinogen deficiencies. Our systematic analysis of the available clinical and genetic data on these disorders evidences their high allelic heterogeneity, the existence of different pathogenic mechanisms, and the absence of strong genotype/phenotype correlations.",
keywords = "Afibrinogenemia, Diagnosis, Fibrinogen, Hypofibrinogenemia, Molecular basis, Mutational spectrum, Symptoms",
author = "Rosanna Asselta and S. Spena and S. Duga and Tenchini, {M. L.}",
year = "2007",
month = "4",
doi = "10.2174/187152507780363205",
language = "English",
volume = "5",
pages = "163--173",
journal = "Cardiovascular and Hematological Agents in Medicinal Chemistry",
issn = "1871-5257",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Molecular genetics of quantitative fibrinogen disorders

AU - Asselta, Rosanna

AU - Spena, S.

AU - Duga, S.

AU - Tenchini, M. L.

PY - 2007/4

Y1 - 2007/4

N2 - Fibrinogen is a complex glycoprotein involved in the final step of the coagulation cascade as the precursor of fibrin monomers that participate in the formation of the haemostatic plug. Three genes (FGA, FGB, and FGG) clustered on chromosome 4q31.3-4q32.1 encode the three polypeptide chains (Aα Bβ, and γ), which in a pairwise fashion form the hexameric circulating molecule. Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen. Patients affected by CAF (Mendelian Inheritance in Man, [MIM] #202400) or severe hypofibrinogenemia (MIM+134820, *134830, and *134850) may experience bleeding manifestations varying from mild to catastrophic. Although many cases of fibrinogen deficiencies have been described from a clinical point of view, only in a minority of cases the causal mutation was identified. The genetic defects so far described, most unique for any analyzed family, are invariantly located in the fibrinogen cluster; for only few of them the pathogenic role either at the protein or at the mRNA level has been investigated. This review, besides providing a concise description of the main structural and functional properties of fibrinogen and giving an overview of the clinical manifestations, the laboratory diagnosis and therapeutic approches, will be focused on the present knowledge on the genetic basis of quantitative fibrinogen deficiencies. Our systematic analysis of the available clinical and genetic data on these disorders evidences their high allelic heterogeneity, the existence of different pathogenic mechanisms, and the absence of strong genotype/phenotype correlations.

AB - Fibrinogen is a complex glycoprotein involved in the final step of the coagulation cascade as the precursor of fibrin monomers that participate in the formation of the haemostatic plug. Three genes (FGA, FGB, and FGG) clustered on chromosome 4q31.3-4q32.1 encode the three polypeptide chains (Aα Bβ, and γ), which in a pairwise fashion form the hexameric circulating molecule. Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen. Patients affected by CAF (Mendelian Inheritance in Man, [MIM] #202400) or severe hypofibrinogenemia (MIM+134820, *134830, and *134850) may experience bleeding manifestations varying from mild to catastrophic. Although many cases of fibrinogen deficiencies have been described from a clinical point of view, only in a minority of cases the causal mutation was identified. The genetic defects so far described, most unique for any analyzed family, are invariantly located in the fibrinogen cluster; for only few of them the pathogenic role either at the protein or at the mRNA level has been investigated. This review, besides providing a concise description of the main structural and functional properties of fibrinogen and giving an overview of the clinical manifestations, the laboratory diagnosis and therapeutic approches, will be focused on the present knowledge on the genetic basis of quantitative fibrinogen deficiencies. Our systematic analysis of the available clinical and genetic data on these disorders evidences their high allelic heterogeneity, the existence of different pathogenic mechanisms, and the absence of strong genotype/phenotype correlations.

KW - Afibrinogenemia

KW - Diagnosis

KW - Fibrinogen

KW - Hypofibrinogenemia

KW - Molecular basis

KW - Mutational spectrum

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=34247619426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247619426&partnerID=8YFLogxK

U2 - 10.2174/187152507780363205

DO - 10.2174/187152507780363205

M3 - Article

C2 - 17430139

AN - SCOPUS:34247619426

VL - 5

SP - 163

EP - 173

JO - Cardiovascular and Hematological Agents in Medicinal Chemistry

JF - Cardiovascular and Hematological Agents in Medicinal Chemistry

SN - 1871-5257

IS - 2

ER -